Fig. 5.

DAS28 [C-reactive protein (CRP)] in from rheumatoid arthritis (RA) patients with or without acute-phase serum amyloid (SAA) normalization. RA patients receiving tofacitinib were divided into patients with an adequate decline in SAA (normalization; <8 ug/ml) and patients with an inadequate SAA decline (without normalization, ≥8 μg/ml) at 4 weeks. DAS28 (CRP) was measured before and at 12 weeks after tofacitinib treatment in both patient groups. There was a significant difference between DAS28 (CRP) before and at 12 weeks in the patients with SAA normalization.